TY - JOUR
T1 - High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction
AU - Pokorney, Sean D.
AU - Radder, Christina
AU - Schulte, Phillip J.
AU - Al-Khatib, Sana M.
AU - Tricocci, Pierluigi
AU - Van De Werf, Frans
AU - James, Stefan K.
AU - Cannon, Christopher P.
AU - Armstrong, Paul W.
AU - White, Harvey D.
AU - Califf, Robert M.
AU - Gibson, C. Michael
AU - Giugliano, Robert P.
AU - Wallentin, Lars
AU - Mahaffey, Kenneth W.
AU - Harrington, Robert A.
AU - Newby, L. Kristin
AU - Piccini, Jonathan P.
N1 - Funding Information:
Dr Pokorney reports modest research grant support from Astra Zeneca, Gilead, and Boston Scientific, and modest advisory board support from Janssen Pharmaceuticals. Ms Radder was supported by a National Institutes of Health training grant ( T32HL079896 ). Dr Schulte and Dr Al-Khatib report no disclosures. Dr Tricoci reports a consultant agreement and research grant from Merck & Co., Inc. Dr Van de Werf reports research support from Merck & Co, Inc, and Boehringer Ingelheim; consultancy for AstraZeneca and Boehringer Ingelheim; and lecture fees from Boehringer Ingelheim and AstraZeneca. Dr James has received research grants from AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Terumo Inc, Medtronic, and Vascular Solutions, and honoraria from The Medicines Company, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, and IROKO, and has served as a consultant/advisory board member for AstraZeneca, Eli Lilly, Merck, Medtronic, and Sanofi. Dr Cannon currently receives research grant support from Accumetrics, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Sanofi-Aventis, and Schering Plough. Dr Armstrong reports research support and consulting fees/honoraria from Merck Sharp & Dohme Corp; consultancy for Eli Lilly, Regado Biosciences, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Sanofi-Aventis, Takeda Pharmaceuticals, and Merck & Co, Inc; and research support from Boehringer Ingelheim, Sanofi-Aventis Canada, GlaxoSmithKline, AstraZeneca, Regado Biosciences, Amylin, and Novartis. Dr White reports research support from Sanofi-Aventis, Eli Lilly, The Medicines Company, the National Institutes of Health, Pfizer, Roche, Johnson & Johnson, Merck Sharpe & Dohme, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo Pharma Development, and Bristol-Myers Squibb, and advisory boards for Merck Sharpe & Dohme and Regado Biosciences. Dr Califf has received consulting fees and grant support from Amylin, Kowa Research Institute, Merck-Schering Plough, Nile, NITROX LLC, Parkview, Bristol Myers Squibb, Novartis, Orexigen Therapeutics, Pozen, Servier International, Johnson & Johnson, Roche, Merck, Regado, Bayer, and Web M.D. Dr Gibson has received consulting fees from Merck-Schering Plough. Dr Giugliano is a consultant to AstraZeneca, Biosite Inc, Biosite Diagnostics, CV Therapeutics, Daiichi Sankyo, Mosby, Novartis Pharmaceutical Company, Proctor and Gamble, Roche Diagnostic Corp, and Scios, and has received grant support from Adolor Corporation, AstraZeneca, BG Medicine, Biosite Inc, Biosite Diagnostics, Bristol-Myers Squibb, Medicure, Sanofi-Aventis, and Schering Plough Corporation. Dr Wallentin reports research support and consulting fees/honoraria from Merck & Co, Inc; consultancy for Regado Biotechnologies, Portola, C.S.L. Behring, Athera Biotechnologies, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, and Pfizer; and research support and lecture fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, and Schering-Plough. Dr Mahaffey's disclosures prior to August 1, 2013, are available at https://www.dcri.org/about-us/conflict-of-interest/Mahaffey-COI_2011-2013.pdf , and disclosures after August 1, 2013, are available at http://med.stanford.edu/profiles/Kenneth_Mahaffey . Dr Harrington has received consulting/advisory board fees from Bristol-Myers Squibb, Sanofi, Portola Pharmaceuticals, Johnson & Johnson, and Merck, and grant support from Eli Lilly/Daiichi-Sankyo, Merck, Portola Pharmaceuticals, Sanofi, Johnson & Johnson, Bristol-Myers Squibb, The Medicines Company, and AstraZeneca. Dr Newby has received research grant funding for EARLY ACS through Duke/Duke Clinical Research Institute from Merck-Schering Plough, Amgen, Inc, Amylin, AstraZeneca, Eli Lilly, Daiichi-Sankyo, dia Dexus, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, Murdock Study, Regado Biosciences, NHLBI, Novartis, and Roche. Dr Piccini reports significant research grant support from ARCA biopharma, Boston Scientific, GE Healthcare, Johnson & Johnson/Janssen Pharmaceuticals, and ResMed; modest consultant/advisory board support from Medtronic, Inc, and Spectranetics, and significant consultant/advisory board support from Johnson & Johnson/Janssen Pharmaceuticals.
Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Background Non-ST-segment myocardial infarction (NSTEMI) can be complicated by high-degree atrioventricular (AV) block, asystole, or electromechanical dissociation (EMD), but these events are not well characterized in the contemporary era. This analysis assesses the incidence of and factors associated with these dysrhythmias in acute NSTEMIs. Methods Patients with NSTEMI in the EARLY ACS, PLATO, and TRACER trials were included in the pooled cohort (N = 29,677). Logistic regression was used to identify factors associated with in-hospital high-degree AV block and asystole or EMD, and Kaplan-Meier methods were used to assess mortality. Results High-degree AV block occurred in 112 (0.4%) patients, asystole in 157 (0.5%), and EMD in 38 (0.1%). Pacemakers were inserted in 241 patients (0.8%) during the index hospitalization: 30 (12%) for AV block. Among patients with high-degree AV block, we observed more frequent right coronary artery lesions (47% vs 29%). Age, diabetes, lower heart rate, and lower blood pressure were associated with high-degree AV block. Higher Killip class, ST-segment depression, prior myocardial infarction, and peripheral vascular disease were most strongly associated with asystole or EMD. Ten-day unadjusted survival was 90% for patients with high-degree AV block and 43% for those with asystole or EMD. Conclusions Although high-degree AV block, asystole, and EMD were infrequent complications of NSTEMI, they were associated with substantial short-term mortality. Only 1 in 8 pacemakers placed in NSTEMI patients during the acute hospitalization was for high-degree AV block.
AB - Background Non-ST-segment myocardial infarction (NSTEMI) can be complicated by high-degree atrioventricular (AV) block, asystole, or electromechanical dissociation (EMD), but these events are not well characterized in the contemporary era. This analysis assesses the incidence of and factors associated with these dysrhythmias in acute NSTEMIs. Methods Patients with NSTEMI in the EARLY ACS, PLATO, and TRACER trials were included in the pooled cohort (N = 29,677). Logistic regression was used to identify factors associated with in-hospital high-degree AV block and asystole or EMD, and Kaplan-Meier methods were used to assess mortality. Results High-degree AV block occurred in 112 (0.4%) patients, asystole in 157 (0.5%), and EMD in 38 (0.1%). Pacemakers were inserted in 241 patients (0.8%) during the index hospitalization: 30 (12%) for AV block. Among patients with high-degree AV block, we observed more frequent right coronary artery lesions (47% vs 29%). Age, diabetes, lower heart rate, and lower blood pressure were associated with high-degree AV block. Higher Killip class, ST-segment depression, prior myocardial infarction, and peripheral vascular disease were most strongly associated with asystole or EMD. Ten-day unadjusted survival was 90% for patients with high-degree AV block and 43% for those with asystole or EMD. Conclusions Although high-degree AV block, asystole, and EMD were infrequent complications of NSTEMI, they were associated with substantial short-term mortality. Only 1 in 8 pacemakers placed in NSTEMI patients during the acute hospitalization was for high-degree AV block.
UR - http://www.scopus.com/inward/record.url?scp=84951788716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951788716&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2015.09.004
DO - 10.1016/j.ahj.2015.09.004
M3 - Article
C2 - 26699597
AN - SCOPUS:84951788716
SN - 0002-8703
VL - 171
SP - 25
EP - 32
JO - American Heart Journal
JF - American Heart Journal
IS - 1
ER -